补肺活血胶囊联合噻托溴铵对COPD稳定期患者肺功能、炎性因子及预后的影响

Effects of bufei huoxue capsule and tiotropium bromide on pulmonary function and inflammatory factors for chronic obstructive pulmonary disease patients

目的研究补肺活血胶囊联合噻托溴铵对慢性阻塞性肺疾病(COPD)稳定期患者肺功能、炎性因子及预后的影响。方法选取120例符合纳入标准的COPD稳定期患者作为研究对象,采用随机数字表法分为2组,每组60例。在常规治疗基础上,对照组患者给予噻托溴铵治疗,观察组在对照组基础上给予补肺活血胶囊联合噻托溴铵治疗。12周后,比较2组患者肺功能、炎性因子水平及预后。结果治疗后,观察组患者肺功能指标第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、FEV1预计值水平分别为(1.87±0.26)L、(64.74±6.88)%、(63.19±5.53)%,低于对照组的(1.72±0.20)L、(58.46±6.53)%、(59.07±5.14)%,差异均有统计学意义(P<0.05);观察组炎性因子白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平分别为(80.15±12.37)ng/L、(4.75±0.47)mg/L、(1.98±0.12)ng/mL,低于对照组的(97.18±15.63)ng/L、(6.13±0.60)mg/L、(2.51±0.17)ng/mL,差异均有统计学意义(P<0.05)。预后方面,观察组患者治疗后症状体征积分为(2.02±0.27)分,低于对照组的(2.91±0.36)分,差异有统计学意义(P<0.05);观察组急性发作次数(1.10±0.51)次,低于对照组的(2.43±1.24)次,差异有统计学意义(P<0.05)。结论补肺活血胶囊联合噻托溴铵在COPD稳定期中应用效果良好,能够有效改善肺功能,减轻炎性反应,改善疾病预后,可在临床上推广应用。

Objective To investigate effects of bufei huoxue capsule in combination with tiotropium bromide on pulmonary function,inflammatory factors and prognosis in patients with chronic obstructive pulmonary disease（COPD）at stable stage.Methods 120 patients of COPD at stable stage meeting the inclusion criteria were selected as research objects.According to random number table,those patients were divided into the control group and the observation group,each group had 60 patients.Besides conventional treatments,the control group was given tiotropium bromide,while the observation group was given bufei huoxue capsule in combination with tiotropium bromide.After 12 weeks,indices of pulmonary function,levels of inflammatory factor and prognosis were compared between the two groups.Results Aftertreatments,pulmonary function indices of forced expiratory volume in one second（FEV1）,FEV1/forced vital capacity（FVC）,FEV1 estimated value in the observation group were（1.87±0.26）L,（64.74±6.88）%,（63.19±5.53）%,lower than control group with（1.72±0.20）L,（58.46±6.53）%,（59.07±5.14）%,the differences were statistically significant（P〈0.05）;levels of inflammatory factors of interleukin-6（IL-6）,C reactive protein（CRP）,tumor necrosis factor-α（TNF-α）in the observation group were（80.15±12.37）ng/L,（4.75±0.47）mg/L,（1.98±0.12）ng/mL,lower than control group with（97.18±15.63）ng/L,（6.13±0.60）mg/L,（2.51±0.17）ng/mL,the differences were statistically significant（P〈0.05）.As to prognosis,score of symptoms in the observation group after the treatments was（2.02±0.27）points,lower than control group with（2.91±0.36）points,the differences were statistically significant（P〈0.05）;the times of acute exacerbation in the observation group was（1.10±0.51）times,lower than control group with（2.43±1.24）times,the differences were statistically significant（P〈0.05）.Conclusion Bufei huoxue capsule in combination with tiotropium bromide is effective in treating patients with COPD at stable stage,which can significantly improve pulmonary function,alleviate inflammatory reaction and improve prognosis.